Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Neoplasms of the CNS

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 83 articles: HTML format

Single Articles

April 2024
1. LOW JCM, Cao J, Hesse F, Wright AJ, et al
   Deuterium metabolic imaging differentiates glioblastoma metabolic subtypes and detects early response to chemoradiotherapy.
   Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-2552.
   PubMed     Abstract available
   
   
   March 2024
2. HWANG GH, Pazyra-Murphy MF, Seo HS, Dhe-Paganon S, et al
   A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma.
   Cancer Res. 2024;84:872-886.
   PubMed     Abstract available
   
   
   February 2024
3. LI J, Shih LK, Brat DJ
   Integrated Proteogenomics Uncover Mechanisms of Glioblastoma Evolution, Pointing to Novel Therapeutic Targets.
   Cancer Res. 2024 Feb 8. doi: 10.1158/0008-5472.CAN-24-0452.
   PubMed     Abstract available
   
   
   January 2024
4. UNDERHILL HR, Karsy M, Davidson CJ, Hellwig S, et al
   Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas.
   Cancer Res. 2024 Jan 25. doi: 10.1158/0008-5472.CAN-23-2557.
   PubMed     Abstract available
   
   
   
5. ZHAO D, Verhaak RGW
   Defining the role of extrachromosomal DNA amplifications in medulloblastoma.
   Cancer Res. 2024 Jan 4. doi: 10.1158/0008-5472.CAN-23-4025.
   PubMed     Abstract available
   
   
   December 2023
6. MALTA TM, Sabedot TS, Morosini NS, Datta I, et al
   The epigenetic evolution of glioma is determined by the IDH1 mutation status and treatment regimen.
   Cancer Res. 2023 Dec 20. doi: 10.1158/0008-5472.CAN-23-2093.
   PubMed     Abstract available
   
   
   
7. WANG D, Yan K, Yu H, Li H, et al
   Fimepinostat impairs NF-kappaB and PI3K/AKT signaling and enhances gemcitabine efficacy in H3K27M-mutated diffuse intrinsic pontine glioma.
   Cancer Res. 2023 Dec 14. doi: 10.1158/0008-5472.CAN-23-0394.
   PubMed     Abstract available
   
   
   November 2023
8. GUO X, Qiu W, Wang C, Qi Y, et al
   Neuronal activity promotes glioma progression by inducing proneural-to-mesenchymal transition in glioma stem cells.
   Cancer Res. 2023 Nov 14. doi: 10.1158/0008-5472.CAN-23-0609.
   PubMed     Abstract available
   
   
   September 2023
9. YIN J, Seo Y, Rhim J, Jin X, et al
   Crosstalk between PARN and EGFR-STAT3 Signaling Facilitates Self-Renewal and Proliferation of Glioblastoma Stem Cells.
   Cancer Res. 2023 Sep 25. doi: 10.1158/0008-5472.CAN-22-3965.
   PubMed     Abstract available
   
   
   May 2023
10. MONDAL I, Das O, Sun R, Gao J, et al
    PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING-Type I Interferon Signaling in Glioblastoma.
    Cancer Res. 2023 May 23:CAN-22-3382. doi: 10.1158/0008-5472.CAN-22-3382.
    PubMed     Abstract available
    
    
    
11. JACKSON ER, Duchatel RJ, Staudt DE, Persson ML, et al
    ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
    Cancer Res. 2023 May 17:OF1-OF17. doi: 10.1158/0008-5472.CAN-23-0186.
    PubMed     Abstract available
    
    
    
12. BAYIK D, Bartels CF, Lovrenert K, Watson DC, et al
    Correction: Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets.
    Cancer Res. 2023;83:1757.
    PubMed    
    
    
    
13. JACKSON ER, Duchatel RJ, Staudt DE, Persson ML, et al
    ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.
    Cancer Res. 2023 May 5:CAN-23-0186. doi: 10.1158/0008-5472.CAN-23-0186.
    PubMed     Abstract available
    
    
    April 2023
14. GUETTA-TERRIER C, Karambizi D, Akosman B, Zepecki JP, et al
    Chi3l1 is a modulator of glioma stem cell states and a therapeutic target in glioblastoma.
    Cancer Res. 2023 Apr 27:CAN-21-3629. doi: 10.1158/0008-5472.CAN-21-3629.
    PubMed     Abstract available
    
    
    
15. MIRZAEI R, D'Mello C, Liu M, Nikolic A, et al
    Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor-Initiating Cells.
    Cancer Res. 2023 Apr 17:OF1-OF17. doi: 10.1158/0008-5472.CAN-22-3004.
    PubMed     Abstract available
    
    
    
16. KARREMAN MA, Bauer AT, Solecki G, Berghoff AS, et al
    Active Remodeling of Capillary Endothelium via Cancer Cell-Derived MMP9 Promotes Metastatic Brain Colonization.
    Cancer Res. 2023;83:1299-1314.
    PubMed     Abstract available
    
    
    March 2023
17. ZAMLER DB, Hu J
    Primitive Oligodendrocyte Precursor Cells Are Highly Susceptible to Gliomagenic Transformation.
    Cancer Res. 2023;83:807-808.
    PubMed     Abstract available
    
    
    
18. PINE AR, Cirigliano SM, Singhania R, Nicholson J, et al
    Microenvironment-driven dynamic chromatin changes in glioblastoma recapitulate early neural development at single-cell resolution.
    Cancer Res. 2023 Mar 6:CAN-22-2872. doi: 10.1158/0008-5472.CAN-22-2872.
    PubMed     Abstract available
    
    
    February 2023
19. GALLON J, Rodriguez-Calero A, Benjak A, Akhoundova D, et al
    DNA methylation landscapes of prostate cancer brain metastasis are shaped by early driver genetic alterations.
    Cancer Res. 2023 Feb 7:CAN-22-2236. doi: 10.1158/0008-5472.CAN-22-2236.
    PubMed     Abstract available
    
    
    January 2023
20. ZHAO M, Li Y, Lu C, Ding F, et al
    PGC-1alpha degradation suppresses mitochondrial biogenesis to confer radiation resistance in glioma.
    Cancer Res. 2023 Jan 25:CAN-22-3083. doi: 10.1158/0008-5472.CAN-22-3083.
    PubMed     Abstract available
    
    
    
21. VERMA R, Chen X, Xin D, Luo Z, et al
    Olig1/2-expressing intermediate lineage progenitors are predisposed to PTEN/p53-loss-induced gliomagenesis and harbor specific therapeutic vulnerabilities.
    Cancer Res. 2023 Jan 12:CAN-22-1577. doi: 10.1158/0008-5472.CAN-22-1577.
    PubMed     Abstract available
    
    
    
22. WU M, Wu L, Wu W, Zhu M, et al
    Phagocytosis of glioma cells enhances the immunosuppressive phenotype of bone marrow-derived macrophages.
    Cancer Res. 2023 Jan 9:CAN-22-1570. doi: 10.1158/0008-5472.CAN-22-1570.
    PubMed     Abstract available
    
    
    December 2022
23. AGNIHOTRI S, Golbourn B, Huang X, Remke M, et al
    Correction: PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma.
    Cancer Res. 2022;82:4695.
    PubMed    
    
    
    November 2022
24. PIERI V, Gallotti AL, Drago D, Cominelli M, et al
    Aberrant L-Fucose accumulation and increased core fucosylation are metabolic liabilities in mesenchymal glioblastoma.
    Cancer Res. 2022 Nov 21:CAN-22-0677. doi: 10.1158/0008-5472.CAN-22-0677.
    PubMed     Abstract available
    
    
    October 2022
25. KUZUOGLU-OZTURK D, Aksoy O, Schmidt C, Lea R, et al
    N-myc mediated translation control is a therapeutic vulnerability in medulloblastoma.
    Cancer Res. 2022 Oct 20. pii: 709870. doi: 10.1158/0008-5472.CAN-22-0945.
    PubMed     Abstract available
    
    
    
26. MOSER JC, Salvador E, Deniz K, Swanson K, et al
    The Mechanisms of Action of Tumor Treating Fields.
    Cancer Res. 2022;82:3650-3658.
    PubMed     Abstract available
    
    
    
27. BORGENVIK A, Holmberg KO, Bolin S, Zhao M, et al
    Dormant SOX9-positive cells facilitate MYC-driven recurrence of medulloblastoma.
    Cancer Res. 2022 Oct 11. pii: 709709. doi: 10.1158/0008-5472.CAN-22-2108.
    PubMed     Abstract available
    
    
    September 2022
28. BAYIK D, Bartels CF, Lovrenert K, Watson DC, et al
    Distinct cell adhesion signature defines glioblastoma myeloid-derived suppressor cell subsets.
    Cancer Res. 2022 Sep 20. pii: 709287. doi: 10.1158/0008-5472.CAN-21-3840.
    PubMed     Abstract available
    
    
    
29. GAN T, Wang Y, Xie M, Wang Q, et al
    MEX3A impairs DNA mismatch repair signaling and mediates acquired temozolomide resistance in glioblastoma.
    Cancer Res. 2022 Sep 16. pii: 709224. doi: 10.1158/0008-5472.CAN-22-2036.
    PubMed     Abstract available
    
    
    
30. SHIELDS JA, Meier SR, Bandi M, Mulkearns-Hubert EE, et al
    VRK1 is a Synthetic Lethal Target in VRK2-deficient Glioblastoma.
    Cancer Res. 2022 Sep 7. pii: 709105. doi: 10.1158/0008-5472.CAN-21-4443.
    PubMed     Abstract available
    
    
    August 2022
31. HESSE F, Wright AJ, Somai V, Bulat F, et al
    Imaging glioblastoma response to radiotherapy using 2H magnetic resonance spectroscopy measurements of fumarate metabolism.
    Cancer Res. 2022 Aug 16. pii: 707755. doi: 10.1158/0008-5472.CAN-22-0101.
    PubMed     Abstract available
    
    
    July 2022
32. LI Y, Wang T, Wan Q, Wang Q, et al
    TRAF4 maintains deubiquitination of Caveolin-1 to drive glioblastoma stemness and Temozolomide resistance.
    Cancer Res. 2022 Jul 27. pii: 707286. doi: 10.1158/0008-5472.CAN-21-3882.
    PubMed     Abstract available
    
    
    
33. DEVAN SP, Jiang X, Luo G, Xie J, et al
    Selective cell size MRI differentiates brain tumors from radiation necrosis.
    Cancer Res. 2022 Jul 25. pii: 707206. doi: 10.1158/0008-5472.CAN-21-2929.
    PubMed     Abstract available
    
    
    
34. LI D, Zhang Q, Li L, Chen K, et al
    beta2-microglobulin maintains glioblastoma stem cells and induces M2-like polarization of tumor-associated macrophages.
    Cancer Res. 2022 Jul 15. pii: 707040. doi: 10.1158/0008-5472.CAN-22-0507.
    PubMed     Abstract available
    
    
    
35. GUO D, Xiao J, Liang J, Fan J, et al
    CDK4/6 inhibition enhances oncolytic virus efficacy by potentiating tumor-selective cell killing and T cell activation in refractory glioblastoma.
    Cancer Res. 2022 Jul 6. pii: 706877. doi: 10.1158/0008-5472.CAN-21-3656.
    PubMed     Abstract available
    
    
    June 2022
36. YI J, Kim B, Shi X, Zhan X, et al
    PRC2 Heterogeneity Drives Tumor Growth in Medulloblastoma.
    Cancer Res. 2022 Jun 22. pii: 705063. doi: 10.1158/0008-5472.CAN-21-4313.
    PubMed     Abstract available
    
    
    
37. KARLOW JA, Devarakonda S, Xing X, Jang HS, et al
    Developmental pathways are epigenetically reprogrammed during lung cancer brain metastasis.
    Cancer Res. 2022 Jun 15. pii: 704908. doi: 10.1158/0008-5472.CAN-21-4160.
    PubMed     Abstract available
    
    
    May 2022
38. BONFILL-TEIXIDOR E, Iurlaro R, Handl C, Wichmann J, et al
    Activity and resistance of a brain-permeable paradox breaker BRAF inhibitor in melanoma brain metastasis.
    Cancer Res. 2022 May 18. pii: 699020. doi: 10.1158/0008-5472.CAN-21-4152.
    PubMed     Abstract available
    
    
    
39. ZHANG B, Peng H, Zhou M, Bao L, et al
    Targeting BCAT1 combined with alpha-ketoglutarate triggers metabolic synthetic lethality in glioblastoma.
    Cancer Res. 2022 May 2. pii: 696261. doi: 10.1158/0008-5472.CAN-21-3868.
    PubMed     Abstract available
    
    
    March 2022
40. GABRIEL NN, Balaji K, Jayachandran K, Inkman M, et al
    Loss of H3K27 trimethylation promotes radiotherapy resistance in medulloblastoma and induces an actionable vulnerability to BET inhibition.
    Cancer Res. 2022 Mar 22. pii: 682339. doi: 10.1158/0008-5472.CAN-21-0871.
    PubMed     Abstract available
    
    
    
41. BINDER ZA, O'Rourke DM
    Glioblastoma: The Current State of Biology and Therapeutic Strategies.
    Cancer Res. 2022;82:769-772.
    PubMed     Abstract available
    
    
    February 2022
42. AUZMENDI-IRIARTE J, Otaegi-Ugartemendia M, Carrasco-Garcia E, Azkargorta M, et al
    Chaperone-mediated autophagy controls proteomic and transcriptomic pathways to maintain glioma stem cell activity.
    Cancer Res. 2022 Feb 7. pii: 0008-5472.CAN-21-2161.
    PubMed     Abstract available
    
    
    December 2021
43. SEN A, Prager BC, Zhong C, Park D, et al
    Leveraging Allele-Specific Expression for Therapeutic Response Gene Discovery in Glioblastoma.
    Cancer Res. 2021 Dec 13. pii: 0008-5472.CAN-21-0810.
    PubMed     Abstract available
    
    
    
44. MAZE EA, Agit B, Reeves S, Hilton DA, et al
    Human endogenous retrovirus type K promotes proliferation and confers sensitivity to anti-retroviral drugs in Merlin-negative schwannoma and meningioma.
    Cancer Res. 2021 Dec 1. pii: 0008-5472.CAN-20-3857.
    PubMed     Abstract available
    
    
    November 2021
45. YANG Z, Hu N, Wang W, Hu W, et al
    Loss of FBXW7 correlates with increased IDH1 expression in glioma and enhances IDH1-mutant cancer cell sensitivity to radiation.
    Cancer Res. 2021 Nov 4. pii: 0008-5472.CAN-21-0384.
    PubMed     Abstract available
    
    
    
46. XING F, Liu Y, Wu SY, Wu K, et al
    Correction: Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis.
    Cancer Res. 2021;81:5582.
    PubMed    
    
    
    September 2021
47. FLETCHER-SANANIKONE E, Kanji S, Tomimatsu N, Macedo Di Cristofaro LF, et al
    Elimination of radiation-induced senescence in the brain tumor microenvironment attenuates glioblastoma recurrence.
    Cancer Res. 2021 Sep 27. pii: 0008-5472.CAN-21-0752.
    PubMed     Abstract available
    
    
    
48. ANSARI KI, Bhan A, Saotome M, Tyagi A, et al
    Autocrine GMCSF Signaling Contributes to Growth of HER2(+) Breast Leptomeningeal Carcinomatosis.
    Cancer Res. 2021;81:4723-4735.
    PubMed     Abstract available
    
    
    
49. LOPES-RAMOS CM, Belova T, Brunner TH, Ben Guebila M, et al
    Regulatory network of PD1 signaling is associated with prognosis in glioblastoma multiforme.
    Cancer Res. 2021 Sep 7. pii: 0008-5472.CAN-21-0730.
    PubMed     Abstract available
    
    
    
50. FAURE C, Djerbi-Bouillie R, Domingot A, Bouzinba-Segard H, et al
    Allosteric inhibition of HER2 by Moesin-mimicking compounds targets HER2-positive cancers and brain metastases.
    Cancer Res. 2021 Sep 7. pii: 0008-5472.CAN-21-0162.
    PubMed     Abstract available
    
    
    
51. ANDERSON NM, Qin X, Finan JM, Lam A, et al
    Metabolic Enzyme DLST Promotes Tumor Aggression and Reveals a Vulnerability to OXPHOS Inhibition in High-Risk Neuroblastoma.
    Cancer Res. 2021;81:4417-4430.
    PubMed     Abstract available
    
    
    August 2021
52. WU AH, Fruin S, Larson TV, Tseng CC, et al
    Association between Airport-Related Ultrafine Particles and Risk of Malignant Brain Cancer: A Multiethnic Cohort Study.
    Cancer Res. 2021;81:4360-4369.
    PubMed     Abstract available
    
    
    July 2021
53. AOKI K, Suzuki H, Yamamoto T, Yamamoto KN, et al
    Mathematical modeling and mutational analysis reveal optimal therapy to prevent malignant transformation in grade II IDH-mutant gliomas.
    Cancer Res. 2021 Jul 31. pii: 0008-5472.CAN-21-0985.
    PubMed     Abstract available
    
    
    
54. NAJM P, Zhao P, Steklov M, Sewduth RN, et al
    Loss-of-function mutations in TRAF7 and KLF4 cooperatively activate RAS-like GTPase signaling and promote meningioma development.
    Cancer Res. 2021 Jul 2. pii: 0008-5472.CAN-20-3669.
    PubMed     Abstract available
    
    
    June 2021
55. BHAN A, Ansari KI, Chen MY, Jandial R, et al
    Inhibition of Jumonji Histone Demethylases Selectively Suppresses HER2(+) Breast Leptomeningeal Carcinomatosis Growth via Inhibition of GMCSF Expression.
    Cancer Res. 2021;81:3200-3214.
    PubMed     Abstract available
    
    
    
56. MO J, Liu F, Sun X, Huang H, et al
    Inhibition of the FACT Complex Targets Aberrant Hedgehog Signaling and Overcomes Resistance to Smoothened Antagonists.
    Cancer Res. 2021;81:3105-3120.
    PubMed     Abstract available
    
    
    May 2021
57. MA R, Lu T, Li Z, Teng KY, et al
    An oncolytic virus expressing IL-15/IL-15Ralpha combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma.
    Cancer Res. 2021 May 18. pii: 0008-5472.CAN-21-0035.
    PubMed     Abstract available
    
    
    
58. MA T, Hu C, Lal B, Zhou W, et al
    Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells.
    Cancer Res. 2021;81:2457-2469.
    PubMed     Abstract available
    
    
    April 2021
59. GAO M, Fu Y, Zhou W, Gui G, et al
    EGFR Activates a TAZ-driven Oncogenic Program in Glioblastoma.
    Cancer Res. 2021 Apr 28. pii: 0008-5472.CAN-20-2773.
    PubMed     Abstract available
    
    
    
60. FILIPPOVA N, Yang X, Ananthan S, Calano J, et al
    Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors.
    Cancer Res. 2021;81:2220-2233.
    PubMed     Abstract available
    
    
    
61. LI M, Kirtane AR, Kiyokawa J, Nagashima H, et al
    Local Targeting of NAD(+) Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma.
    Cancer Res. 2021;81:1922.
    PubMed    
    
    
    March 2021
62. JALALI A, Yu K, Beechar V, Bosquez Huerta N, et al
    POT1 regulates proliferation and confers sexual dimorphism in glioma.
    Cancer Res. 2021 Mar 29. pii: 0008-5472.CAN-20-3755.
    PubMed     Abstract available
    
    
    February 2021
63. SEGURA-COLLAR B, Garranzo-Asensio M, Herranz B, Hernandez-SanMiguel E, et al
    Tumor-derived pericytes driven by EGFR mutations govern the vascular and immune microenvironment of gliomas.
    Cancer Res. 2021 Feb 16. pii: 0008-5472.CAN-20-3558.
    PubMed     Abstract available
    
    
    
64. DAY EK, Zhong Q, Purow B, Lazzara MJ, et al
    Data-driven computational modeling identifies determinants of glioblastoma response to SHP2 inhibition.
    Cancer Res. 2021 Feb 11. pii: 0008-5472.CAN-20-1756.
    PubMed     Abstract available
    
    
    
65. SUTCLIFFE MD, Galvao RP, Wang L, Kim J, et al
    Premalignant oligodendrocyte precursor cells stall in a heterogeneous state of replication stress prior to gliomagenesis.
    Cancer Res. 2021 Feb 2. pii: 0008-5472.CAN-20-1037.
    PubMed     Abstract available
    
    
    January 2021
66. OH H, Hwang I, Jang JY, Wu L, et al
    Therapy-induced transdifferentiation promotes glioma growth independent of EGFR signaling.
    Cancer Res. 2021 Jan 28. pii: 0008-5472.CAN-20-1810.
    PubMed     Abstract available
    
    
    
67. BERG TJ, Marques C, Pantazopoulou V, Johansson E, et al
    The irradiated brain microenvironment supports glioma stemness and survival via astrocyte-derived Transglutaminase 2.
    Cancer Res. 2021 Jan 22. pii: 0008-5472.CAN-20-1785.
    PubMed     Abstract available
    
    
    
68. NOR C, Ramaswamy V
    Next-Generation Profiling of Medulloblastoma: Old Drugs Are an Elegant Weapon in a Civilized Age.
    Cancer Res. 2021;81:264-265.
    PubMed     Abstract available
    
    
    December 2020
69. NEY GM, McKay L, Koschmann C, Mody R, et al
    The Emerging Role of Ras Pathway Signaling in Pediatric Cancer.
    Cancer Res. 2020;80:5155-5163.
    PubMed     Abstract available
    
    
    November 2020
70. LI J, Liao T, Liu H, Yuan H, et al
    Hypoxic glioma stem cell-derived exosomes containing Linc01060 promote progression of glioma by regulating the MZF1/c-Myc/HIF-1alpha.
    Cancer Res. 2020 Nov 6. pii: 0008-5472.CAN-20-2270.
    PubMed     Abstract available
    
    
    October 2020
71. SARMIENTO SOTO M, Larkin JR, Martin C, Khrapitchev AA, et al
    STAT3-mediated astrocyte reactivity associated with brain metastasis contributes to neurovascular dysfunction.
    Cancer Res. 2020 Oct 26. pii: 0008-5472.CAN-20-2251.
    PubMed     Abstract available
    
    
    
72. RESTALL IJ, Cseh O, Richards LM, Pugh TJ, et al
    Brain tumor stem cell dependence on glutaminase reveals a metabolic vulnerability through the amino acid deprivation response pathway.
    Cancer Res. 2020 Oct 26. pii: 0008-5472.CAN-19-3923.
    PubMed     Abstract available
    
    
    
73. TATEISHI K, Miyake Y, Kawazu M, Sasaki N, et al
    A hyperactive RelA/p65-hexokinase 2 signaling axis drives primary central nervous system lymphoma.
    Cancer Res. 2020 Oct 16. pii: 0008-5472.CAN-20-2425.
    PubMed     Abstract available
    
    
    
74. RUSERT JM, Juarez EF, Brabetz S, Jensen J, et al
    Functional precision medicine identifies new therapeutic candidates for medulloblastoma.
    Cancer Res. 2020 Oct 12. pii: 0008-5472.CAN-20-1655.
    PubMed     Abstract available
    
    
    
75. VOLI F, Valli E, Lerra L, Kimpton K, et al
    Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion.
    Cancer Res. 2020;80:4129-4144.
    PubMed     Abstract available
    
    
    September 2020
76. LI M, Kirtane AR, Kiyokawa J, Nagashima H, et al
    Local targeting of NAD+ salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-20-1094.
    PubMed     Abstract available
    
    
    August 2020
77. DUNCAN RM, Reyes L, Moats K, Robinson RM, et al
    ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors.
    Cancer Res. 2020;80:3279-3291.
    PubMed     Abstract available
    
    
    July 2020
78. MONJE M
    Synaptic Communication in Brain Cancer.
    Cancer Res. 2020;80:2979-2982.
    PubMed     Abstract available
    
    
    
79. WU F, Zhang C, Zhao C, Wu H, et al
    Prostaglandin E1 Inhibits GLI2 Amplification-Associated Activation of the Hedgehog Pathway and Drug Refractory Tumor Growth.
    Cancer Res. 2020;80:2818-2832.
    PubMed     Abstract available
    
    
    April 2020
80. LOPEZ-BERTONI H, Kotchetkov IS, Mihelson N, Lal B, et al
    A Sox2:miR-486-5p Axis Regulates Survival of GBM Cells by Inhibiting Tumor Suppressor Networks.
    Cancer Res. 2020;80:1644-1655.
    PubMed     Abstract available
    
    
    
81. CHANDRA A, Jahangiri A, Chen W, Nguyen AT, et al
    Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
    Cancer Res. 2020;80:1498-1511.
    PubMed     Abstract available
    
    
    March 2020
82. TAN AW, Weljie AM
    Metabolite Imaging at the Margin: Visualizing Metabolic Tumor Gradients Using Mass Spectrometry.
    Cancer Res. 2020;80:1231-1233.
    PubMed     Abstract available
    
    
    February 2020
83. HEBERT JD, Myers SA, Naba A, Abbruzzese G, et al
    Proteomic profiling of the ECM of xenograft breast cancer metastases in different organs reveals distinct metastatic niches.
    Cancer Res. 2020 Feb 4. pii: 0008-5472.CAN-19-2961.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.